The Global Liposomal Doxorubicin Market size was accounted for US$ 1.3 Billion in 2023 and. Is expected to reach US$ 1.9 Billion in 2031, & is anticipated to reflect a CAGR of 6.7% during the period of 2024-2031. This growth is primarily driven by the increasing prevalence of various cancers, including breast, ovarian, and multiple myeloma, which necessitates more effective and targeted...